Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).

To describe and compare the changes in renal function between HIV-1 infected adult patients receiving antiretroviral therapy (ART) with and without tenofovir (TDF). The population consisted of 40 patients starting a TDF-containing regimen and 388 patients starting regimen not containing TDF, and followed during 42 months. The estimated glomerular filtration rate (eGFR) was calculated using the Cockroft-Gault and MDRD equations and modeled separately for the first 12 months and the subsequent period. Between baseline and 12 months, the eGFR decreased significantly in patients receiving TDF (-10.40 ml/min), whereas it increased in the other +4.33 ml/min). A significant variability in the eGFR trajectories of patients receiving TDF was observed; 12 (30%) of them experienced a persistent decrease, 5 (12%) had an initial transient increase, and 23 (58%) a steady slow increase in eGFR. The characteristics at baseline of the patients with persistent decrease were not different from the other patients but their immune reconstitution was impaired. After 12 months, patients receiving TDF experienced a higher rate of transition from mild renal impairment (60-90 ml/min/1.73 m(2)) to moderate renal impairment (30-60 ml/min/1.73 m(2)) when compared with patients not receiving TDF. A significant though moderate decline in the renal function was observed in one-third of the patients receiving TDF compared to patients not receiving TDF. Moreover, this impairment was persistent after the first year of treatment.

[1]  M. Perazella,et al.  Nephrotoxicity of HAART , 2011, AIDS research and treatment.

[2]  Geert Molenberghs,et al.  Random Effects Models for Longitudinal Data , 2010 .

[3]  Richard D Moore,et al.  Renal function with use of a tenofovir-containing initial antiretroviral regimen , 2009, AIDS.

[4]  E. Delaporte,et al.  Tenofovir-Emtricitabine-Efavirenz in HIV-I-Infected Adults in Senegal: A 96-Week Pilot Trial in Treatment-Naive Patients , 2009, Journal of the International Association of Physicians in AIDS Care.

[5]  A. Copas,et al.  Tenofovir‐associated renal and bone toxicity , 2009, HIV medicine.

[6]  G. Cooke,et al.  Renal impairment in a rural African antiretroviral programme , 2009, BMC Infectious Diseases.

[7]  E. Kinai,et al.  Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. , 2009, AIDS research and human retroviruses.

[8]  V. Soriano,et al.  Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir , 2009, AIDS.

[9]  E. Overton,et al.  Factors associated with renal dysfunction within an urban HIV‐infected cohort in the era of highly active antiretroviral therapy , 2009, HIV medicine.

[10]  J. Gallant,et al.  The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients , 2008, AIDS.

[11]  P. Peters,et al.  Antiretroviral therapy improves renal function among HIV-infected Ugandans. , 2008, Kidney international.

[12]  C. Gilks,et al.  Estimating Glomerular Filtration Rate in HIV-Infected Adults in Africa: Comparison of Cockcroft–Gault and Modification of Diet in Renal Disease Formulae , 2008, Antiviral therapy.

[13]  I. Williams,et al.  Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  L. Szczech,et al.  Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease , 2008, AIDS.

[15]  H. Furrer,et al.  Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study , 2007, Antiviral therapy.

[16]  A. Taburet,et al.  Renal Function in Antiretroviral-Experienced Patients treated with Tenofovir Disoproxil Fumarate associated with Atazanavir/ritonavir , 2007, Antiviral therapy.

[17]  P. Ramdial,et al.  A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. , 2006, Kidney international.

[18]  E. Delaporte,et al.  Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study , 2006, AIDS.

[19]  A. Winston,et al.  Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy , 2006, HIV medicine.

[20]  K. Weissenborn,et al.  Neurological and neuropsychiatric syndromes associated with liver disease. , 2005, AIDS.

[21]  Karen Bandeen-Roche,et al.  Residual Diagnostics for Growth Mixture Models , 2005 .

[22]  F. Goebel,et al.  Progression of renal impairment under therapy with tenofovir. , 2005, AIDS.

[23]  Richard D Moore,et al.  Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  J. Gallant,et al.  Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  S. Mauss,et al.  Antiretroviral therapy with tenofovir is associated with mild renal dysfunction , 2005, AIDS.

[26]  B. Gazzard,et al.  Renal Dysfunction With Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral Therapy Regimens Is Not Observed More Frequently: A Cohort and Case-Control Study , 2004, Journal of acquired immune deficiency syndromes.

[27]  L. Svetkey,et al.  The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. , 2004, Kidney international.

[28]  J. Hulot,et al.  Renal safety of tenofovir in HIV treatment-experienced patients , 2004, AIDS.

[29]  Ethan M Balk,et al.  Erratum: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification (Annals of Internal Medicine (2003) 139 (137-147)) , 2003 .

[30]  E. Delaporte,et al.  Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal , 2003, AIDS.

[31]  J. Rossert,et al.  Fanconi syndrome and renal failure induced by tenofovir: a first case report. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  M. Perazella,et al.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. , 2002, The American journal of the medical sciences.

[33]  F. Liégeois,et al.  The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study , 2002, AIDS.

[34]  Daniel Zelterman,et al.  Modeling Survival Data: Extending the Cox Model , 2002, Technometrics.

[35]  Philip Hougaard,et al.  Analysis of Multivariate Survival Data , 2001 .

[36]  D. Rubin,et al.  Testing the number of components in a normal mixture , 2001 .

[37]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[38]  Daniel S. Nagin,et al.  Analyzing developmental trajectories: A semiparametric, group-based approach , 1999 .

[39]  D. DuBois,et al.  A formula to estimate the approximate surface area if height and weight be known , 1989 .

[40]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[41]  D. D. Bois,et al.  CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN , 1916 .

[42]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[43]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .